Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
47 studies found for:    Open Studies | "hospital of central connecticut"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "hospital of central connecticut"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Cardiovascular Inflammation Reduction Trial
Condition: Cardiovascular Disease
Interventions: Drug: Methotrexate;   Drug: Placebo
2 Recruiting Connect® MM- The Multiple Myeloma Disease Registry
Condition: Multiple Myeloma
Intervention:
3 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
4 Recruiting CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
Conditions: Atypical Endocervical Glandular Cell of Undetermined Significance;   Atypical Endometrial Hyperplasia;   Human Papillomavirus Infection;   Stage 0 Cervical Cancer
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
5 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib;   Biological: Rituximab;   Drug: Bendamustine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
6 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Docetaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
7 Recruiting Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer
Interventions: Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
8 Recruiting Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Cisplatin;   Radiation: Internal Radiation Therapy
9 Recruiting Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Condition: Endometrial Cancer
Interventions: Drug: Carboplatin/Paclitaxel;   Drug: Trastuzumab
10 Recruiting S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Condition: Kidney Cancer
Interventions: Drug: everolimus;   Other: placebo
11 Recruiting Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Conditions: Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary-Mucinous Neoplasm;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: Gemcitabine Hydrochloride;   Drug: Erlotinib Hydrochloride;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Capecitabine;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
12 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Letrozole;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
13 Recruiting Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
Interventions: Drug: Lenalidomide;   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
14 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Trametinib;   Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis
15 Recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Major Salivary Gland Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma;   Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
Interventions: Drug: Docetaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Fluorouracil;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Cytology Specimen Collection Procedure
16 Recruiting Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Behavioral: behavioral dietary intervention;   Behavioral: exercise intervention;   Other: counseling intervention;   Other: educational intervention;   Behavioral: compliance monitoring;   Other: questionnaire administration;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
17 Recruiting Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Conditions: Gestational Trophoblastic Tumor;   Good Prognosis Metastatic Gestational Trophoblastic Tumor;   Hydatidiform Mole;   Uterine Corpus Choriocarcinoma
Interventions: Drug: Leucovorin Calcium;   Biological: Dactinomycin;   Drug: Methotrexate;   Other: Quality-of-Life Assessment
18 Recruiting COOL-ARREST Pilot Study to Assess Intravascular Temperature Management (IVTM) in the Treatment of Cardiac Arrest
Condition: Out of Hospital Cardiac Arrest
Intervention: Device: ZOLL Intravascular Temperature Management System (IVTM)
19 Recruiting Study Comparing AEZS-108/ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) to Doxorubicin as a Second Line Therapy of Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Drug: AEZS-108 / zoptarelin doxorubicin;   Drug: doxorubicin
20 Recruiting Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva
Conditions: Stage IIIA Vulvar Cancer;   Stage IIIB Vulvar Cancer;   Stage IIIC Vulvar Cancer;   Stage IVA Vulvar Cancer;   Vulvar Squamous Cell Carcinoma
Interventions: Radiation: Intensity-Modulated Radiation Therapy;   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Procedure: Therapeutic Conventional Surgery

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years